Alvine Pharmaceuticals
Alvine Pharmaceuticals is a San Carlos, California-based private biotechnology company founded in 2005 that develops therapeutics for autoimmune and inflammatory diseases, backed by Sofinnova, Flagship Pioneering, and InterWest Partners across venture rounds totaling approximately $68 million.
- Company typePrivate
- Founded2005
- HeadquartersSan Carlos, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alvine Pharmaceuticals does
Alvine Pharmaceuticals is a privately held clinical-stage biotechnology company founded in 2005 and headquartered in San Carlos, California. Per the input data, the company develops therapeutics for autoimmune and inflammatory diseases, with operations supported by 11-50 employees. Scientific direction is anchored by founder Chaitan S. Khosla, a Stanford-based scientist, complemented by a board of directors that includes Bill Ringo, Patrick Gage, David Schnell, and Michael Powell.
The firm has deployed a venture-backed biotech business model, raising approximately $68 million across five financing rounds between 2006 and 2013. Capital was sourced from a syndicate of biotech-focused investors including Sofinnova Investments, Flagship Pioneering, InterWest Partners, Black River Asset Management, Panorama Capital, and Prospect Venture Partners, with Sofinnova and Prospect co-leading earlier rounds. The largest single financing was a $26.5M round in March 2011, followed by two $6M follow-on financings in October 2011 and January 2013, suggesting a transition to bridge/extension financing in the company's most recent visible capital activity.
The input data does not enumerate specific drug candidates, clinical-stage assets, indications under development, partnerships, licensing arrangements, or revenue figures. Consequently, the company's commercial mechanism, pricing model, and product-level technical architecture cannot be characterized from the source material. The post-2013 silence in the data is a material caveat for any forward-looking assessment.
Alvine Pharmaceuticals firmographics
Firmographics- Name
- Alvine Pharmaceuticals
- Legal name
- CANDU123.COM
- Website
- https://alvinepharma.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alvine Pharmaceuticals is a San Carlos, California-based private biotechnology company founded in 2005 that develops therapeutics for autoimmune and inflammatory diseases, backed by Sofinnova, Flagship Pioneering, and InterWest Partners across venture rounds totaling approximately $68 million.
- Ownership category
- akta.pro rank
Alvine Pharmaceuticals industry classification
Industry- Product category
- Immunology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Alvine Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Markets served
Alvine Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Alvine Pharmaceuticals product offering
Product offeringCore offering
Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases. The company focuses on protein-based drug candidates targeting conditions in immunology, with operations based in San Carlos, United States, and was founded in 2005.
Product overview
No information available about Alvine Pharmaceuticals products and services.
Differentiator
Problem solved
Functional benefit
Companies that use Alvine Pharmaceuticals
Customer profileIdeal customer profiles1 record
Alvine Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Alvine Pharmaceuticals partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
Alvine Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Sanofi: Co-marketer of Dupixent, a flagship autoimmune/inflammation biologic. Comparable peer given its leadership position in immunology and ongoing M&A in the space.
- AbbVie: Global immunology leader anchored by Humira and Skyrizi/Rinvoq. Comparable to Alvine as a major developer and commercializer of autoimmune/inflammatory therapeutics, though far broader in scope and scale.
- Amgen: Large-cap biotech with a significant inflammation/autoimmune franchise (e.g., Enbrel, Otezla). Relevant incumbent peer given overlapping therapeutic focus and biologic modality.
- Johnson & Johnson (Janssen): Janssen's immunology unit markets Stelara, Tremfya, and Remicade. Comparable as a leading commercializer of autoimmune biologics with deep pipeline investment.
- Regeneron Pharmaceuticals: Developer of Dupixent and other inflammation biologics. Comparable as a biologics-driven company with a strong autoimmune/inflammation franchise and pipeline.
- Bristol-Myers Squibb: Owns Zeposia and other immunology assets. Comparable as a major player with significant autoimmune/inflammation R&D and commercial presence.
- Vertex Pharmaceuticals: Mid-to-large biotech expanding from cystic fibrosis into autoimmune and inflammatory diseases (e.g., VX-548, JAK programs). Comparable as a science-driven biotech with growing autoimmune ambitions.
Emerging players
- AnaptysBio: Clinical-stage biotech developing antibody therapeutics for inflammation and autoimmune disease. Comparable as a focused autoimmune-focused biotech at a similar development stage.
- ChemoCentryx: Autoimmune-focused biotech (acquired by Amgen in 2022) that developed Tavalisse and Tavneos. Comparable as a small-cap autoimmune specialist eventually absorbed by a larger player — a plausible Alvine outcome.
- Protagonist Therapeutics: Clinical-stage biotech developing peptide-based therapeutics for autoimmune and inflammatory diseases. Comparable given similar size, modality innovation, and therapeutic area focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Alvine Pharmaceuticals social profiles
Digital presenceAlvine Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alvine Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles5 records
Alvine Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alvine Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alvine Pharmaceuticals
What does Alvine Pharmaceuticals do?
Alvine Pharmaceuticals is a biotechnology company developing therapeutics for autoimmune and inflammatory diseases. The company focuses on protein-based drug candidates targeting conditions in immunology, with operations based in San Carlos, United States, and was founded in 2005.
Is Alvine Pharmaceuticals a public or private company?
Alvine Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alvine Pharmaceuticals founded?
Alvine Pharmaceuticals was founded in 2005. It employs 11 to 50 people.
Where is Alvine Pharmaceuticals based?
Alvine Pharmaceuticals is headquartered in San Carlos, United States, in the North America region.
Who are Alvine Pharmaceuticals's main competitors?
Broad incumbents on record are Sanofi, AbbVie, Amgen, Johnson & Johnson (Janssen), Regeneron Pharmaceuticals, Bristol-Myers Squibb and Vertex Pharmaceuticals. Emerging players are AnaptysBio, ChemoCentryx and Protagonist Therapeutics.
Does Alvine Pharmaceuticals have an API?
No public API is recorded for Alvine Pharmaceuticals.
What industry is Alvine Pharmaceuticals in?
Alvine Pharmaceuticals's product category is Immunology Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.